Spots Global Cancer Trial Database for angiogenesis inhibitors
Every month we try and update this database with for angiogenesis inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | NCT00635193 | Ovarian Cancer,... | M200 (Volocixim... Liposomal Doxor... M200 (Volocixim... M200 (Volocixim... | 18 Years - | AbbVie | |
| Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | NCT06075849 | Solid Tumor, Ad... Solid Tumor Gastric Cancer Hepatocellular ... Metastatic Colo... Advanced Solid ... | PB101 | 19 Years - | Panolos Bioscience | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | NCT01204749 | Fallopian Tube ... Ovarian Cancer Primary Periton... | AMG 386 AMG 386 Placebo Paclitaxel Paclitaxel | 18 Years - | Amgen | |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | NCT06134193 | Carcinoma Intrahepatic Ch... Gallbladder Can... Surufatinib Angiogenesis In... Tislelizumab Antineoplastic ... Immunotherapy | HAIC Surufatinib Tislelizumab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Apatinib in Advanced Non-squamous，NSCLC | NCT03376191 | Non-squamous No... | apatinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | NCT00644124 | Lymphoma, Non-H... | aflibercept | 18 Years - | Sanofi | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | NCT00861419 | Advanced Solid ... | Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386 | 18 Years - | Amgen | |
| Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy | NCT00657098 | Metastatic Mali... | 18 Years - | University Medical Center Groningen | ||
| Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy | NCT00657098 | Metastatic Mali... | 18 Years - | University Medical Center Groningen | ||
| A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. | NCT02034006 | Choroidal Neova... | Ranibizumab | 18 Years - | Novartis | |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | NCT00861419 | Advanced Solid ... | Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386 | 18 Years - | Amgen | |
| A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | NCT01525550 | Well-differenti... | sunitinib | 18 Years - | Pfizer | |
| Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | NCT00644124 | Lymphoma, Non-H... | aflibercept | 18 Years - | Sanofi | |
| Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | NCT06075849 | Solid Tumor, Ad... Solid Tumor Gastric Cancer Hepatocellular ... Metastatic Colo... Advanced Solid ... | PB101 | 19 Years - | Panolos Bioscience | |
| Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer | NCT01683994 | Prostatic Neopl... | Cabozantinib Docetaxel Prednisone | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 | NCT00602862 | Clear Cell Rena... | Sorafenib 111Indium-bevac... 111Indium-cG250 | 18 Years - | Radboud University Medical Center | |
| A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors | NCT01137552 | Advanced Solid ... | AMG 780 | 18 Years - | Amgen | |
| Apatinib in Advanced Non-squamous，NSCLC | NCT03376191 | Non-squamous No... | apatinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma | NCT00520533 | Renal Cell Carc... | Chimeric monocl... Sunitinib malat... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | NCT01525550 | Well-differenti... | sunitinib | 18 Years - | Pfizer | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
